# Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

> **NCT05204563** · PHASE3 · COMPLETED · sponsor: **Evopoint Biosciences Inc.** · enrollment: 450 (actual)

## Conditions studied

- Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

## Interventions

- **DRUG:** Combination of Imipenem/Cilastatin and XNW4107
- **DRUG:** Imipenem/Cilastatin/Relebactam

## Key facts

- **NCT ID:** NCT05204563
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-31
- **Primary completion:** 2024-09-29
- **Final completion:** 2024-09-29
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05204563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05204563, "Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05204563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*